Dyfyniad APA

Saba, N. F. (2017). Commentary: Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study). Front Oncol.

Dyfyniad Arddull Chicago

Saba, Nabil F. "Commentary: Randomized Phase II Study of Duligotuzumab (MEHD7945A) Vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study)." Front Oncol 2017.

Dyfyniad MLA

Saba, Nabil F. "Commentary: Randomized Phase II Study of Duligotuzumab (MEHD7945A) Vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study)." Front Oncol 2017.

Rhybudd: Mae'n bosib nad yw'r dyfyniadau hyn bob amser yn 100% cywir.